Filing Details

 

	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. )*

 

Rain Oncology Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

75082Q 10 5

(CUSIP Number)

 

April 23, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 75082Q 10 5
	1.	Names of Reporting Persons Samsara BioCapital, L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0
			6.		Shared Voting Power 2,260,652  shares (2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 2,260,652 shares (2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,260,652  shares (2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
	11.	Percent of Class Represented by Amount in Row (9) 9.1% (3)
	12.	Type of Reporting Person (See Instructions) PN

(1)

This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP and Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2022.

(3)

This percentage is calculated based on 24,763,488 shares of Common Stock outstanding as of as of November 8, 2022 as reported in the Issuer’s prospectus supplement dated November 3, 2022, filed on November 7, 2022 with the Securities and Exchange Commission.

 

 

CUSIP No. 75082Q 10 5
	1.	Names of Reporting Persons Samsara BioCapital GP, LLC
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0
			6.		Shared Voting Power 2,260,652  shares (2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 2,260,652  shares (2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,260,652  shares (2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
	11.	Percent of Class Represented by Amount in Row (9) 9.1% (3)
	12.	Type of Reporting Person (See Instructions) OO

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2022.

(3)

This percentage is calculated based on 24,763,488 shares of Common Stock outstanding as of as of November 8, 2022 as reported in the Issuer’s prospectus supplement dated November 3, 2022, filed on November 7, 2022 with the Securities and Exchange Commission.

 

 

CUSIP No. 75082Q 10 5
	1.	Names of Reporting Persons Dr. Srinivas Akkaraju
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)
	3.	SEC Use Only
	4.	Citizenship or Place of Organization United States of America
Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0
			6.		Shared Voting Power 2,260,652 shares (2)
			7.		Sole Dispositive Power 0
			8.		Shared Dispositive Power 2,260,652 shares (2)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,260,652 shares (2)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
	11.	Percent of Class Represented by Amount in Row (9) 9.1% (3)
	12.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2022.

(3)

This percentage is calculated based on 24,763,488 shares of Common Stock outstanding as of as of November 8, 2022 as reported in the Issuer’s prospectus supplement dated November 3, 2022, filed on November 7, 2022 with the Securities and Exchange Commission.

 

Item 1.
	(a)	Name of Issuer Rain Oncology Inc.
	(b)	Address of Issuer’s Principal Executive Offices 8000 Jarvis Avenue, Suite 204 Newark, CA 94560
Item 2.
	(a)	Name of Person Filing Samsara BioCapital, L.P. (“Samsara LP”) Samsara BioCapital GP, LLC (“Samsara GP”) Srinivas Akkaraju (“Akkaraju”)
	(b)	Address of Principal Business Office or, if none, Residence c/o Samsara BioCapital, LLC 628 Middlefield Road Palo Alto, CA 94301
	(c)	Citizenship

	Entities:	Samsara LP	-	Delaware
		Samsara GP	-	Delaware
	Individuals:	Akkaraju	-	United States of America

	(d)	Title of Class of Securities Common Stock, par value $0.001 per share
	(e)	CUSIP Number 75082Q 10 5
Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	Not applicable.

 

Item 4.	Ownership
The beneficial ownership information set forth below is provided as of December 31, 2022:

 

Reporting Persons		Shares Held Directly				Sole Voting Power			Shared Voting Power				Sole Dispositive Power			Shared Dispositive Power				Beneficial Ownership				Percentage of Class (3)
Samsara LP (1) (2)			2,260,652							2,260,652							2,260,652				2,260,652				9.1	%
Samsara GP (1) (2)										2,260,652							2,260,652				2,260,652				9.1	%
Akkaraju (1) (2)										2,260,652							2,260,652				2,260,652				9.1	%

 

	(1)	Includes 2,260,652 shares of Common Stock held by Samsara LP.
	(2)	Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
	(3)	This percentage is calculated based on 24,763,488 shares of Common Stock outstanding as of as of November 8, 2022 as reported in the Issuer’s prospectus supplement dated November 3, 2022, filed on November 7, 2022 with the Securities and Exchange Commission.

 

 

Item 5.	Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
Not applicable.
Item 8.	Identification and Classification of Members of the Group
Not applicable.
Item 9.	Notice of Dissolution of Group
Not applicable.
Item 10.	Certification
By signing below, each of the undersigned certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 14, 2023

 

Samsara BioCapital, L.P.			Samsara BioCapital GP, LLC
By:	Samsara BioCapital GP, LLC		By:	/s/ Srinivas Akkaraju
its	General Partner			Name: Srinivas Akkaraju
				Title: Managing Member
By:	/s/ Srinivas Akkaraju
	Name: Srinivas Akkaraju
	Title: Managing Member
	/s/ Srinivas Akkaraju
	Srinivas Akkaraju

 

	ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).